Results 231 to 240 of about 54,905 (262)

Prognostic Significance of Bile Duct Loss in Early‐Stage Primary Biliary Cholangitis: A Long‐Term Observational Study

Hepatology Research, Volume 55, Issue 12, Page 1621-1630, December 2025.
Bile duct loss on liver biopsy predicts future liver‐related events in early‐stage primary biliary cholangitis, even in patients with preserved liver function. This finding highlights the prognostic value of histological bile duct assessment at diagnosis and may guide early risk stratification and management decisions.
Taiki Okumura, Takefumi Kimura, Takanobu Iwadare, Shun‐Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Akihiro Matsumoto, Tomoyuki Nakajima, Mai Iwaya, Masahiro Umemura, Kazuhito Kawata, Kenichi Harada, Takeji Umemura   +15 more
wiley   +1 more source

Pathology reporting of hepatoblastoma resections: recommendations from the international collaboration on cancer reporting

Histopathology, Volume 87, Issue 6, Page 802-814, December 2025.
This is the first international dataset for the reporting of hepatoblastoma resection specimens produced by the International Collaboration on Cancer Reporting (ICCR). The aim is to standardize pathology reports, facilitating international data comparisons and improving management of hepatoblastoma on a global level.
Dolores H López‐Terrada, Fleur Webster, Rita Alaggio, Jonathan W Bush, Soo‐Jin Cho, Ronald R de Krijger, Takeshi Inoue, Allison F O'Neill, Antonio R Perez‐Atayde, Sarangarajan Ranganathan, Jens Stahlschmidt, Yukichi Tanaka, Marta Cohen, Miguel Reyes‐Múgica   +13 more
wiley   +1 more source

Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open‐label clinical trial (RESOLUTION study)

Journal of Diabetes Investigation, Volume 16, Issue 12, Page 2160-2172, December 2025.
Luseogliflozin alleviated renal function decline (eGFR) after an initial decrease, showing renoprotective effects in patients with renal impairment. Luseogliflozin did not increase renal events, showing safety even in patients with moderate‐to‐severe renal impairment.
Munehiro Kitada, Masao Toyoda, Osamu Sekine, Daisuke Suzuki, Yosuke Okada, Yoshikata Morita, Hideki Nishimura, Hiroaki Satoh, Hideki Kamiya, Toshinari Takamura, Motohide Isono, Takeshi Onoue, Hiroshi Arima, Kenichi Tanaka, Masaji Miyamoto, Yasushi Omura, Daisuke Yabe, Takehiro Kato, Akimichi Asano, Yutaka Wakasa, Satoshi Miyamoto, Shinji Kume, Tomohiko Ito, Shin‐ichi Araki, Atsushi Nakagawa, RESOLUTION Study Investigators   +25 more
wiley   +1 more source

Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update

Journal of Viral Hepatitis, Volume 32, Issue 12, December 2025.
ABSTRACT Chronic hepatitis Delta (CHD) represents the most aggressive form of viral hepatitis. In the latest estimates, published in 2024 by the Polaris Observatory, the overall prevalence of the hepatitis Delta virus (HDV) in Hepatitis B surface antigen (HBsAg) + patients was estimated to be 2% worldwide, a lower figure than what was previously ...
Pietro Lampertico, Maria Paola Anolli, Katja Steppich, Heiner Wedemeyer   +3 more
wiley   +1 more source

Comparable 5‐Year Survival in People With and Without HIV Following Hepatocellular Carcinoma Diagnosis: A Multicenter Study

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background and Aims Conflicting data on hepatocellular carcinoma (HCC) survival in people with HIV (PWH) may depend on tumour aggressiveness and access to curative treatments. We compared outcomes of two HCC cohorts according to HIV status.
Massimo Iavarone, Eleonora Alimenti, Massimo Puoti, Hamid Hasson, Bianca Monti, Sherrie Bhoori, Francesco Peracchi, Alessia Siribelli, Marco Fava, Mariangela Bruccoleri, Marco Merli, Giulia Morsica, Annalisa De Silvestri, Paolo Bonfanti, Antonella Castagna, Alessandro Soria, Pietro Lampertico   +16 more
wiley   +1 more source

GLP‐1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background and Aims GLP‐1 receptor agonists (GLP‐1RA) are widely used in type 2 diabetes mellitus (T2DM) and may confer hepatoprotective effects in metabolic dysfunction‐associated steatotic liver disease (MASLD). Their impact on liver fibrosis progression in real‐world clinical settings remains unclear.
Jonggi Choi, Tushar Kamath, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung   +9 more
wiley   +1 more source

Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background and Aims Steatotic liver disease (SLD) affects more than 30% of the global population; however, trends in its prevalence remain poorly understood. This study aimed to elucidate prevalence trends of metabolic dysfunction‐associated steatotic liver disease (MASLD), MASLD with moderate alcohol intake (MetALD), and alcohol‐associated ...
Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu   +5 more
wiley   +1 more source

Osteopenia in primary biliary cirrhosis. Study in 20 patients Osteopenia en cirrosis biliar primaria. Estudio en 20 pacientes.

, 1994
Diego Pumarino, Javier Brahm Barril, Oviedo, Nicolás Lillo, Larry Javier González González   +4 more
openalex   +1 more source

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 498-527, November/December 2025.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source